Skip to content

The Establishment and Accuracy Study of a Target-controlled Infusion(TCI) Model of Ciprofol

The Establishment and Accuracy Study of a Target-controlled Infusion(TCI) Model of Ciprofol

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071603
Enrollment
Unknown
Registered
2023-05-19
Start date
2023-05-20
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

Case series:N/A

Sponsors

Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age 18~85 years old. 2. Patients who plan to undergo elective non-cardiac, non-cranial surgery under general anesthesia with an expected operative timing > 60 minutes. 3. ASA ?~?. No severe systemic diseases or severe anemia, with normal coagulation function. Cardiopulmonary, hepatic and renal functions and biochemical indicators are in the normal compensatory range. 4. Consent to participate and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. BMI > 32 or < 17.5 2. severely impaired heart function (unable to cope with daily activities) 3. abnormal coagulation function, liver and kidney function 4. severe pulmonary dysfunction (including pneumonia, pulmonary atelectasis, pleural effusion, acute lung injury, ARDS) 5. severe circulatory instability (severe coronary artery disease, unstable angina, left ventricular ejection fraction <30%, sick sinus syndrome, severe sinus bradycardia <50 bpm, second-degree or worse atrioventricular block) 6. pregnancy 7. neurological dysfunction 8. predictable difficult airway 9. patients with a history of long-term analgesic or sedative medication 10. hypovolemia 11. abnormal body temperature 12. known allergy or intolerance to the drug being tried 13. refusal to participate in the study 14. participation in other clinical trials within 30 days prior to randomization

Design outcomes

Primary

MeasureTime frame
plasma concentration of ciprofol in arterial;

Countries

China

Contacts

Public ContactLiqun Yang

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

lqyang72721@126.com+86 159 2196 9001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026